Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$107.78 USD
-0.74 (-0.68%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $107.76 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 501 - 516 ( 516 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2 EPS; Important Data Readouts from Three Ph 1 Studies Ahead, Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1 EPS; BLU-554 and BLU-285 Dose Escalations Continue, Preliminary Data Updates Expected YE:16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology AACR Roundup for Covered Companies.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Presents RET Inhibitor Program BLU-667 Data at AACR, IND Submission Expected 2H:16, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC and Roche to Collaborate on Targeting Kinases in Immuno-Oncology
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4:15 EPS, BLU-285 Enters Second Ph 1 Study, Data-Rich 2016 Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
3Q EPS: Systemic Mastocytosis Study Set to Initiate, New Preclinical Programs Revealed, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2:EPS; Multiple Studies on Track for Initiation in 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1:EPS; Looking to Mid:15 IND Submissions for Lead Product Candidates BLU-285 and BLU-554
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $41 Price Target; A Template for Targeted Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D